Title |
Novel pharmacologic treatment in acute binge eating disorder – role of lisdexamfetamine
|
---|---|
Published in |
Neuropsychiatric Disease and Treatment, April 2016
|
DOI | 10.2147/ndt.s80881 |
Pubmed ID | |
Authors |
Anna I Guerdjikova, Nicole Mori, Leah S Casuto, Susan L McElroy |
Abstract |
Binge eating disorder (BED) is the most common eating disorder and an important public health problem. It is characterized by recurrent episodes of excessive food consumption accompanied by a sense of loss of control over the binge eating behavior without the inappropriate compensatory weight loss behaviors of bulimia nervosa. BED affects both sexes and all age groups and is associated with medical and psychiatric comorbidities. Until recently, self-help and psychotherapy were the primary treatment options for patients with BED. In early 2015, lisdexamfetamine dimesylate, a prodrug stimulant marketed for attention deficit hyperactive disorder, was the first pharmacologic agent to be approved by the US Food and Drug Administration for the treatment of moderate or severe BED in adults. This article summarizes BED clinical presentation, and discusses the pharmacokinetic profile, efficacy, and safety of lisdexamfetamine dimesylate in the treatment of BED in adults. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 3 | 43% |
Unknown | 4 | 57% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 4 | 57% |
Practitioners (doctors, other healthcare professionals) | 3 | 43% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 118 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 20 | 17% |
Researcher | 17 | 14% |
Student > Master | 13 | 11% |
Other | 10 | 8% |
Student > Ph. D. Student | 7 | 6% |
Other | 17 | 14% |
Unknown | 34 | 29% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 25 | 21% |
Psychology | 16 | 14% |
Neuroscience | 7 | 6% |
Pharmacology, Toxicology and Pharmaceutical Science | 7 | 6% |
Social Sciences | 5 | 4% |
Other | 19 | 16% |
Unknown | 39 | 33% |